Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Buy” by Analysts

Annovis Bio, Inc. (NYSE:ANVS) has been given a consensus rating of “Buy” by the six ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $37.00.

Separately, D. Boral Capital reissued a “hold” rating on shares of Annovis Bio in a research report on Monday, February 10th.

Institutional Trading of Annovis Bio

Several institutional investors have recently added to or reduced their stakes in ANVS. JPMorgan Chase & Co. acquired a new stake in shares of Annovis Bio during the third quarter worth $31,000. Lokken Investment Group LLC raised its stake in Annovis Bio by 49.0% in the 4th quarter. Lokken Investment Group LLC now owns 18,235 shares of the company’s stock worth $92,000 after purchasing an additional 6,000 shares in the last quarter. State Street Corp boosted its holdings in Annovis Bio by 23.7% in the 3rd quarter. State Street Corp now owns 36,035 shares of the company’s stock valued at $290,000 after purchasing an additional 6,900 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Annovis Bio during the 3rd quarter worth approximately $76,000. Finally, Northern Trust Corp increased its holdings in shares of Annovis Bio by 49.4% during the fourth quarter. Northern Trust Corp now owns 32,780 shares of the company’s stock worth $165,000 after purchasing an additional 10,846 shares during the period. 15.83% of the stock is currently owned by institutional investors.

Annovis Bio Stock Up 7.4 %

Shares of NYSE ANVS opened at $1.60 on Thursday. The business’s 50 day moving average price is $2.47 and its two-hundred day moving average price is $5.38. The company has a market cap of $22.78 million, a PE ratio of -0.36 and a beta of 1.65. Annovis Bio has a twelve month low of $1.43 and a twelve month high of $20.00.

Annovis Bio (NYSE:ANVS) last posted its earnings results on Friday, March 21st. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). During the same period last year, the business earned ($0.43) earnings per share. As a group, research analysts anticipate that Annovis Bio will post -2.19 EPS for the current fiscal year.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.